Table 2.

Analysis of predicted and observed risks in the Women's Health Study.

	0-<5%	5-<7.5%	7.5-<10%	10%+
N	21,639	2,479	1,400	2,024
Predicted risk (%)	1.92	6.13	8.62	15.60
Observed risk (%)	1.01	3.20	6.04	10.79
E/O Ratio	1.90	1.91	1.43	1.45
Sensitivity analyses
Statin RR=0.75
Adjusted observed risk (%)	1.03	3.32	6.28	11.23
E/O Ratio	1.87	1.85	1.37	1.39
Statin RR=0.75, Indication=2.0
Adjusted observed risk (%)	1.04	3.40	6.44	11.54
E/O Ratio	1.84	1.80	1.34	1.35
Statin RR = Revasc RR =0.75, Indication for each =2.0
Adjusted observed risk (%)	1.04	3.41	6.47	11.60
E/O Ratio	1.84	1.80	1.33	1.35
Chol Med RR=0.75, Indication=2.0
Adjusted observed risk (%)	1.04	3.43	6.50	11.67
E/O Ratio	1.83	1.79	1.33	1.34
Chol Med RR = Revasc RR =0.75, Indication for each =2.0
Adjusted observed risk (%)	1.05	3.44	6.53	11.72
E/O Ratio	1.83	1.78	1.32	1.33
Among Non-Diabetics, not on on Chol Meds at Baseline, LDL 70-189
Predicted risk (%)	1.89	6.12	8.61	14.96
Observed risk (%)	0.94	2.70	5.82	9.53
E/O Ratio	2.02	2.26	1.48	1.57
Chol Med RR = Revasc RR =0.75, Indication for each =2.0
Adjusted observed risk (%)	0.96	2.85	6.14	10.02
E/O Ratio	1.97	2.15	1.40	1.49
Censoring at Chol Meds
Predicted risk (%)	1.90	6.12	8.62	15.56
Observed risk (%)	0.96	3.05	6.50	11.13
E/O Ratio	1.99	2.01	1.33	1.40
Censoring at Chol Meds or Revasc
Observed risk (%)	0.95	2.94	6.33	10.91
E/O Ratio	2.00	2.08	1.36	1.43

Abbreviations: E/O Ratio, Expected-to-observed ratio; Chol Meds, use of cholesterol-lowering medication; Revasc, revascularization procedure; RR, relative risk due to intervention; Indication, relative risk associated with confounding by indication; LDL, low-density lipoprotein cholesterol.